Medicine,
‍Redefined.

We are pioneering Hybrid Drugs™ – a new therapeutic category that integrates traditional medication with innovative digital interventions.

Hybrid Drugs enhance motor, cognitive, and mental function - measurably improving outcomes via app-delivered digital daily protocols.

Enter Hybrid DrugsTM

Two Mechanisms. One Unified Treatment.

Remepy’s Hybrid Drugs are not "apps paired with pills." They’re integrated therapeutic systems designed to trigger two distinct but complementary mechanisms of action:

01 The Molecule

Two Mechanisms. One Unified Treatment.

Remepy’s Hybrid Drugs are not "apps paired with pills." They’re integrated therapeutic systems designed to trigger two distinct but complementary mechanisms of action:

02 The Protocol

The Behavioral-Digital Pathway

A regulated, adaptive digital layer targets the neural and behavioral circuits that drugs cannot reach. Through specific, research-based motor, cognitive, and autonomic interventions, this layer rewrites neural patterns and reinforces therapeutic routines.

The Result

A synergistic effect where the drug enables function, and the digital protocol reinforces it, delivering superior clinical outcomes that neither could achieve alone.

Why Chemistry Alone Is No Longer Enough

For decades, medicine has relied on a single modality: chemistry. While pharmaceuticals excel at targeting biological pathways, they don't address the full complexity of human health.

Chronic conditions are driven by more than just biology. They’re influenced by behavior, cognitive state, and patient lifestyle. Traditional drugs are static; they don't adapt to the patient’s changing needs once they leave the pharmacy. To improve outcomes, we need medicines that address both the biology of the disease and the reality of the patient.

Medicines That Learn & Adapt

Unlike a static pill, a Hybrid Drug evolves. Our proprietary platform uses real-time data to personalize the intervention to the patient's specific profile.

  • Personalized Dosing & Support

    The digital layer adjusts based on the patient's daily fluctuations.

  • Neuroplastic Engagement

    Protocols are designed to engage specific brain networks—such as the motor cortex in Parkinson’s or stress-regulation pathways in Oncology.

  • Continuous
    Care

    The treatment doesn't stop when the pill is swallowed; it provides continuous therapeutic engagement at home.

  • Single Source of Care

    Consolidating all relevant therapies into one unified platform simplifies the daily routine, making it easier for patients to follow and significantly improving long-term adherence.

Regulated Like a Drug. Reimbursed Like a Drug.

Hybrid Drugs represent a fundamental shift in how digital health is delivered. We do not sell "wellness apps." We develop regulated therapeutics.

  • FDA Pathways

    Our assets are developed under FDA SaMD-Drug (Software as a Medical Device) or PDURS (Prescription Drug Use-Related Software) pathways.

  • Clinical Validation

    We hold our products to the same rigorous standards as traditional pharma, with Phase 2 and Phase 3 clinical trials validating efficacy.

  • Seamless Access

    Prescribed by doctors and reimbursed by payers, fitting seamlessly into the existing healthcare infrastructure.

Applying the Hybrid Model

We are currently applying our Hybrid Drug platform to some of the most complex challenges in medicine. We target drugs for diseases where meaningful changes to brain connectivity, changes to the immune system, and behavioral changes are synergistic with drug effects. Current focus areas include:

Parkinson’s Disease

Description: Our lead asset, Hybridopa™, combines Levodopa with a digital protocol targeting motor rigidity and cognitive resilience.

Status: Phase 2 Completed. Phase 3 Scheduled Q3 2026.

Oncology

Description: Addressing the high burden of toxicity & distress in cancer treatment. Our hybrid approach aims to improve tolerability and extend survival outcomes through autonomic regulation.

Status: Strategic Partnership / In Development.

Women's Health

Description: Targeting underserved conditions where hormonal biology and behavioral health intersect, offering a new standard of care for complex, life-stage specific conditions.

Status: In Development.

Partner with the Pioneer.

Remepy is defining the next era of pharmaceutical development. We partner with top-tier pharma companies to extend the lifecycle of their assets and improve patient outcomes.